Securities Code: 300683
Securities Abbreviation: Hite Bio
Announcement No.: 2026-034
Wuhan Hite Bio-pharmaceutical Co., Ltd.
Announcement on Receiving Notice of Approval for Clinical Trial of ZM-02 Ophthalmic Injection by Investee Company
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Recently, Wuhan Hite Bio-pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") investee Zhongmou Medical Technology (Wuhan) Co., Ltd. (hereinafter referred to as "Zhongmou Medical") received the "Notice of Approval for Drug Clinical Trial" (Notice No.: 2026LP02339) issued by the National Medical Products Administration, approving its independently developed ZM-02 ophthalmic injection for clinical trials. The Company is pleased to announce that the clinical trial application for ZM-02 ophthalmic injection has been approved by the National Medical Products Administration, and the product will proceed with clinical trials for the treatment of advanced retinitis pigmentosa. The relevant situation is hereby announced as follows:
I. Basic Information of the Drug